Manipulation of citrulline availability in humans

To determine whether circulating citrulline can be manipulated in vivo in humans, and, if so, whether citrulline availability affects the levels of related amino acids, nitric oxide, urinary citrulline, and urea nitrogen, 10 healthy volunteers were studied on 3 separate days: 1) under baseline conditions; 2) after a 24-h treatment with phenylbutyrate (0.36 g center dot kg(-1)center dot day(-1)), a glutamine "trapping" agent; and 3) during oral L- citrulline supplementation ( 0.18 g center dot kg(-1)center dot day(-1)), in randomized order. Plasma, erythrocyte ( RBC), and urinary citrulline concentrations were determined by gas chromatography-mass spectrometry at 3- h intervals between 1100 and 2000 on each study day. Regardless of treatment, RBC citrulline was lower than plasma citrulline, with an RBC- to- plasma ratio of 0.60 +/- 0.04, and urinary citrulline excretion accounted for < 1% of the citrulline load filtered by kidney. Phenylbutyrate induced an similar to 7% drop in plasma glutamine ( P = 0.013), and 18 +/- 14% ( P < 0.0001) and 19 +/- 17% ( P < 0.01) declines in plasma and urine citrulline, respectively, with no alteration in RBC citrulline. Oral L- citrulline administration was associated with 1) a rise in plasma, urine, and RBC citrulline ( 39 +/- 4 vs. 225 +/- 44 mu mol/l, 0.9 +/- 0.3 vs. 6.2 +/- 3.8 mu mol/ mmol creatinine, and 23 +/- 1 vs. 52 +/- 9 mu mol/l, respectively); and 2) a doubling in plasma arginine level, without altering blood urea or urinary urea nitrogen excretion, and thus enhanced nitrogen balance. We conclude that 1) depletion of glutamine, the main precursor of citrulline, depletes plasma citrulline; 2) oral citrulline can be used to enhance systemic citrulline and arginine availability, because citrulline is bioavailable and very little citrulline is lost in urine; and 3) further studies are warranted to determine the mechanisms by which citrulline may enhance nitrogen balance in vivo in humans.